These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 28549755)
1. Cholesterol and stroke: Roll of PCSK9 inhibitors. Castilla-Guerra L; Fernández-Moreno MC; Rico-Corral MA Neurologia (Engl Ed); 2019 Apr; 34(3):198-203. PubMed ID: 28549755 [TBL] [Abstract][Full Text] [Related]
2. [PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know]. Corral P; Ruiz AJ Hipertens Riesgo Vasc; 2017; 34(4):176-183. PubMed ID: 28709786 [TBL] [Abstract][Full Text] [Related]
3. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. Bittner VA; Giugliano RP; Brinton EA; Guyton JR J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750 [TBL] [Abstract][Full Text] [Related]
6. PCSK9 Biology and Its Role in Atherothrombosis. Barale C; Melchionda E; Morotti A; Russo I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931 [TBL] [Abstract][Full Text] [Related]
7. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Tavori H; Melone M; Rashid S Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL; J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591 [TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008 [TBL] [Abstract][Full Text] [Related]
11. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281 [TBL] [Abstract][Full Text] [Related]
12. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]. Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076 [TBL] [Abstract][Full Text] [Related]
13. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia. Schmitz J; Gouni-Berthold I Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217 [TBL] [Abstract][Full Text] [Related]